Hormone Replacement Therapy (HRT): Benefits, Risks, and What to Ask Your Doctor

Hormone replacement therapy (HRT) is the most effective treatment available for menopause symptoms — reducing hot flashes by 75-90% and providing significant relief for sleep disruption, mood changes, joint pain, and vaginal dryness. Modern evidence, including updated analysis of the landmark 2002 WHI study and the 2022 Menopause Society position statement, confirms that HRT is safe for most women when started within 10 years of menopause onset or before age 60. The decision to use HRT is personal and involves weighing your individual risk factors, symptom severity, and preferences in partnership with your doctor.

Last Updated: April 7, 2026

Medical disclaimer: This article is for educational purposes only and does not constitute medical advice. HRT is a prescription treatment that requires evaluation by a qualified healthcare provider. Never start, stop, or modify hormone therapy without medical supervision. Your doctor can assess your individual risk factors and recommend the appropriate approach for your situation.

What Is HRT?

Hormone replacement therapy replaces the hormones your ovaries stop producing during and after menopause — primarily estrogen and, when needed, progesterone. The concept is straightforward: menopause symptoms are caused by hormone depletion, so restoring those hormones alleviates the symptoms.

There are two main categories:

Estrogen-only HRT is prescribed for women who have had a hysterectomy (uterus removed). Without a uterus, there’s no risk of endometrial (uterine lining) overgrowth from unopposed estrogen. Estrogen-only therapy has the most favorable risk profile of any HRT type.

Combined HRT (estrogen + progestogen) is prescribed for women who still have a uterus. The progestogen is added to protect the uterine lining — estrogen alone would stimulate lining growth that could eventually lead to endometrial cancer. The progestogen counteracts this effect. “Progestogen” is the umbrella term that includes both natural progesterone (bioidentical micronized progesterone) and synthetic progestins — and the distinction between them matters for risk, as we’ll cover below.

One crucial clarification: the HRT prescribed today is not the same as what made headlines in 2002. Formulations have evolved significantly. Transdermal estrogen (patches and gels), bioidentical hormones, and lower doses have changed the risk-benefit equation. Understanding this evolution is essential to making an informed decision.

The WHI Study: What Actually Happened (and What Was Misunderstood)

In 2002, the Women’s Health Initiative (WHI) published results that caused millions of women worldwide to stop HRT virtually overnight. The study found increased risks of breast cancer, heart disease, stroke, and blood clots in women taking combined HRT. Headlines were alarming. Doctors pulled prescriptions. A generation of women was left to manage menopause symptoms without the most effective tool available.

Here’s what the headlines didn’t explain.

The study enrolled the wrong age group for the question being asked. The average participant was 63 years old — more than a decade past menopause. Many enrolled women had pre-existing cardiovascular risk factors. The study was designed to test whether HRT could prevent heart disease in older women, not whether it was safe for newly menopausal women using it for symptom relief. These are fundamentally different questions.

Subsequent analysis revealed the “timing hypothesis.” When researchers re-analyzed WHI data by age group, the picture changed dramatically. Women who started HRT within 10 years of menopause showed a significantly different risk profile than those who started it a decade or more later. Younger initiators had lower cardiovascular risk — and in the estrogen-only arm, actually showed reduced coronary heart disease and reduced mortality.

The absolute risk numbers were small. The WHI found approximately 8 additional cases of breast cancer per 10,000 women per year with combined HRT — or roughly 1 additional case per 1,250 women annually. Presented as relative risk (“26% increase”), this sounded frightening. Presented as absolute risk (“less than 1 in 1,000”), the picture is more nuanced. For context, the breast cancer risk increase from combined HRT is comparable to drinking 1-2 glasses of alcohol daily or being obese — risks that most women aren’t warned about with the same intensity.

Estrogen-only HRT did not increase breast cancer risk. The WHI’s estrogen-only arm (for women without a uterus) actually showed a statistically significant decrease in breast cancer risk. This finding is often overlooked in the blanket “HRT causes breast cancer” narrative.

The scientific consensus has shifted substantially since 2002. The 2017 NICE guidelines, the North American Menopause Society, and the International Menopause Society all now state that the benefits of HRT outweigh the risks for most symptomatic women under 60 or within 10 years of menopause.

Benefits of HRT

The evidence for HRT’s benefits is strong and spans multiple systems.

Hot Flash Relief

HRT is the gold standard. It reduces hot flash frequency by 75-90% and significantly decreases their severity. No supplement, lifestyle change, or alternative therapy comes close to this level of relief. For women having 10+ hot flashes daily — disrupting work, sleep, and quality of life — this difference is transformative. Most women notice improvement within 2-4 weeks of starting HRT.

Bone Density Preservation

Estrogen is essential for bone maintenance. After menopause, women lose bone density at an accelerated rate — up to 2-3% per year in the first 5-7 years. HRT slows this loss effectively, reducing fracture risk by approximately 30-40%. For women at risk of osteoporosis, this is a significant benefit. The bone-protective effect persists only while taking HRT — bone loss resumes after stopping, though starting from a higher baseline.

Cardiovascular Protection (When Started Early)

This is where the timing hypothesis is most important. Women who start HRT within 10 years of menopause show reduced coronary artery calcification, improved blood vessel function, and a favorable cardiovascular risk profile. A 2016 study in the New England Journal of Medicine (the ELITE trial) demonstrated that early HRT initiation slowed the progression of atherosclerosis, while late initiation did not. Estrogen helps maintain blood vessel flexibility and healthy cholesterol ratios — benefits that matter most when the cardiovascular system hasn’t yet accumulated significant damage.

Improved Sleep

Estrogen and progesterone both influence sleep architecture. HRT — particularly formulations that include micronized progesterone (which has natural sedative properties via GABA receptor activation) — often improves both sleep onset and sleep maintenance. For women whose primary menopause complaint is waking at 3 AM drenched in sweat and unable to fall back asleep, the sleep benefit of HRT may be as valuable as the hot flash reduction.

Joint Pain and Stiffness

Estrogen has anti-inflammatory and joint-protective properties. Many women on HRT report meaningful improvement in the morning stiffness and joint aching that appeared during menopause. A 2018 post-hoc analysis of the WHI found that HRT was associated with reduced joint pain and lower rates of joint replacement surgery.

Vaginal and Urinary Health

Estrogen maintains the tissue health of the vagina, vulva, and lower urinary tract. After menopause, these tissues become thinner, drier, and more fragile — a condition called genitourinary syndrome of menopause (GSM) that affects up to 50% of postmenopausal women and worsens over time without treatment. Systemic HRT helps, and local vaginal estrogen is extremely effective for GSM specifically. See our libido article for more on addressing vaginal dryness and sexual health.

Cognitive Support

Estrogen receptors are abundant in brain regions involved in memory and cognition. The 2022 KEEPS-Continuation study and other research suggest that early HRT initiation may support cognitive function during the menopausal transition. This is an active area of research — we don’t yet have definitive evidence that HRT prevents dementia, but the cognitive decline many women experience during menopause often improves with estrogen restoration.

Risks of HRT (In Context)

Honest risk assessment requires putting numbers in context. Raw statistics without context create fear that prevents informed decision-making.

Breast Cancer

Combined HRT (estrogen + progestogen) is associated with a small increased risk of breast cancer after approximately 5 years of use — roughly 1 additional case per 1,000 women per year (WHI data). To calibrate this: the same level of additional risk is associated with drinking 1-2 alcoholic beverages daily, being obese, or leading a sedentary lifestyle. These are real risks that deserve attention — but they don’t make combined HRT uniquely dangerous.

Estrogen-only HRT does not increase breast cancer risk and may decrease it slightly based on the WHI estrogen-only arm.

The type of progestogen matters. A large French cohort study (E3N, 2008) found that micronized progesterone combined with estrogen did not significantly increase breast cancer risk, while synthetic progestins did. This is one reason many clinicians now prefer micronized progesterone (bioidentical) over older synthetic progestins.

Blood Clots

Oral estrogen increases the risk of venous thromboembolism (blood clots in deep veins or lungs). This is a real risk, primarily in the first year of use, and is higher in women who smoke, are obese, or have a personal/family history of clots.

The critical nuance: transdermal estrogen (patches, gels) does not carry this elevated clot risk. A 2019 meta-analysis in the BMJ confirmed that transdermal estrogen is not associated with increased venous thromboembolism. This is a major reason that transdermal delivery has become the preferred route for most prescribers.

Stroke

The WHI found a modestly increased stroke risk with oral HRT, primarily in women over 60. For women under 60 starting transdermal HRT, the stroke risk increase is minimal to nonexistent. Again, delivery method and timing matter enormously.

What the Risk Profile Looks Like in Practice

For a healthy woman under 60, starting transdermal estrogen with micronized progesterone within 10 years of menopause: the cardiovascular risks are minimal, the breast cancer risk is small and dose/duration dependent, and the benefits — symptom relief, bone protection, cardiovascular support, quality of life — are substantial. This is the calculus behind the current consensus position that benefits outweigh risks for most symptomatic women in this demographic.

Types of HRT

Understanding the options helps you have a more productive conversation with your doctor.

Transdermal Estrogen (Patches and Gels)

Estrogen delivered through the skin — either as patches applied once or twice weekly, or as a daily gel. This is the preferred delivery method for most women because it avoids the liver’s first-pass metabolism (estrogen absorbed through the skin goes directly into the bloodstream rather than being processed by the liver first). This bypasses the clotting factor changes that oral estrogen causes, resulting in no increased blood clot risk. Patches are convenient and maintain steady estrogen levels. Gels offer dose flexibility.

Oral Estrogen

Estrogen tablets taken daily. These are effective but carry higher blood clot and stroke risk compared to transdermal forms because the estrogen passes through the liver, affecting clotting factor production. Oral estrogen may still be appropriate for some women, particularly those at low baseline clot risk, but transdermal is generally preferred.

Vaginal Estrogen

Estrogen applied locally as a cream, ring, or tablet directly to vaginal tissue. Minimal systemic absorption — the estrogen stays local, treating GSM symptoms (dryness, thinning, urinary issues) without significant whole-body effects. This is the safest form of estrogen therapy and is considered appropriate even for many breast cancer survivors (confirm with your oncologist). Vaginal estrogen can be used alone for GSM or alongside systemic HRT.

Progesterone Options

If you have a uterus, you’ll need progestogen to protect the endometrial lining. Micronized progesterone (brand name Prometrium) is bioidentical — structurally identical to the progesterone your body makes. It carries a more favorable breast cancer and cardiovascular risk profile than synthetic progestins and has the added benefit of mild sedative properties (helpful for sleep when taken at bedtime). Synthetic progestins (like medroxyprogesterone acetate, used in the WHI) are effective for endometrial protection but carry higher risk. Most current guidelines favor micronized progesterone when possible.

The Mirena IUD as Progestogen Delivery

Some clinicians prescribe a levonorgestrel IUD (Mirena) to provide the progestogen component locally to the uterus, while using transdermal estrogen for systemic relief. This approach delivers progestogen where it’s needed (the uterine lining) while minimizing systemic progestogen exposure. It’s gaining popularity, though guidelines are still evolving on this approach.

Who Should Consider HRT

Good candidates:

• Under 60 or within 10 years of menopause onset
• Moderate to severe vasomotor symptoms (hot flashes, night sweats) affecting quality of life
• No contraindications (see below)
• Interested in bone protection (especially with osteoporosis risk factors)
• Experiencing genitourinary syndrome of menopause
• Premature menopause (before age 40) — HRT is typically recommended until the average age of natural menopause (51) to replace hormones that would otherwise still be present

Who should NOT take HRT (absolute contraindications):

• Personal history of breast cancer (discuss with oncologist — vaginal estrogen may still be an option)
• History of blood clots or pulmonary embolism (transdermal may be considered in some cases with specialist input)
• Active liver disease
• Unexplained vaginal bleeding (must be evaluated first)
• History of estrogen-dependent cancer (endometrial, certain ovarian cancers)
• History of stroke or heart attack

Gray areas requiring specialist discussion:

• Strong family history of breast cancer (risk assessment tools like GAIL or Tyrer-Cuzick can help quantify individual risk)
• Migraine with aura (associated with stroke risk — transdermal estrogen at low doses may be appropriate)
• High cardiovascular risk factors (smoking, uncontrolled hypertension, diabetes)
• Personal preference against hormonal treatment (completely valid — supplements and lifestyle approaches can still provide meaningful relief)

HRT vs. Supplements: An Honest Comparison

This needs to be said plainly: HRT and supplements are not equivalent in effectiveness for menopause symptoms. Presenting them as interchangeable options would be misleading.

Hot flash reduction: HRT reduces hot flashes by 75-90%. Black cohosh (Remifemin) reduces them by 26-50%. Other supplements provide even less relief. If you’re having 12 hot flashes a day and they’re disrupting your work, sleep, and relationships, the difference between 90% reduction and 40% reduction is the difference between getting your life back and still struggling.

Bone density: HRT preserves bone density effectively. No supplement has been shown to have an equivalent bone-protective effect. Calcium and vitamin D support bone health but don’t replace the estrogen-driven bone maintenance that HRT provides.

Vaginal health: Vaginal estrogen (local HRT) is dramatically more effective than any supplement for genitourinary syndrome of menopause. Supplements like sea buckthorn oil have modest evidence — not in the same league.

Cardiovascular protection: HRT started early may provide cardiovascular benefit. No supplement has demonstrated comparable cardiovascular protection during the menopausal transition.

Where supplements have a role:

• Mild symptoms that are bothersome but not significantly impairing quality of life. A 30-50% reduction in hot flash frequency from black cohosh may be enough.
• Women who can’t take HRT due to medical contraindications (breast cancer history, clot history, etc.). Supplements are the available option and still provide some relief.
• Women who prefer not to use HRT. This is a valid choice. Informed refusal is different from uninformed avoidance. If you understand the relative effectiveness and still prefer supplements, that’s your right.
• Complementary use alongside HRT. Some women use magnesium for sleep, ashwagandha for stress, or maca for libido in addition to HRT. These can address symptoms that HRT doesn’t fully resolve.

Read our best menopause supplements guide and hot flash supplements review for detailed evidence on supplement options.

Questions to Ask Your Doctor

If you’re considering HRT, bring these questions to your appointment. They’ll help ensure you have a productive, informed conversation rather than a rushed one.

1. “Based on my personal and family history, what is my individual risk profile for HRT?” Your doctor should assess your breast cancer risk (family history, BRCA status if known), cardiovascular risk factors, clot history, and liver health — not just apply generic population-level statistics.

2. “Would you recommend transdermal estrogen or oral? Why?” The answer should account for your clot risk, cardiovascular profile, and personal preference. If they default to oral without discussing transdermal, ask why.

3. “What type of progestogen would you prescribe, and why?” If you have a uterus, the progestogen choice matters. Ask specifically about micronized progesterone (bioidentical) versus synthetic progestins and the rationale for their recommendation.

4. “What dose do you recommend starting with, and how will we adjust?” Most clinicians now follow a “start low, go slow” approach — beginning with the lowest effective dose and titrating up based on symptom response. Ask about the adjustment timeline.

5. “How long can I safely stay on HRT?” Current guidelines support use for as long as the benefits outweigh the risks for the individual woman, reassessed annually. There’s no hard cutoff, but the conversation about continuing should happen every year.

6. “What symptoms should prompt me to contact you?” Know the warning signs (unusual bleeding, sudden severe headache, leg swelling, chest pain) that warrant immediate medical attention.

7. “If I decide against HRT now, can I start later?” The timing window matters. Understanding that the optimal window is within 10 years of menopause helps you make a timely decision without feeling pressured.

Frequently Asked Questions

Is HRT safe to take long-term? For most women who start HRT within 10 years of menopause, the benefits outweigh the risks for at least 5-7 years, and many clinicians now support longer use based on individual assessment. The primary concern with long-term combined HRT (estrogen plus progestogen) is a small increase in breast cancer risk after roughly 5 years of use — about 1 additional case per 1,000 women per year. Estrogen-only HRT (for women without a uterus) does not carry this increased breast cancer risk. Your doctor should reassess annually whether continuing HRT makes sense for your situation.

Does HRT cause breast cancer? Combined HRT (estrogen plus synthetic progestogen) is associated with a small increase in breast cancer risk after approximately 5 years of use — roughly 1 additional case per 1,000 women per year. To put that in perspective, the risk increase is comparable to drinking 1-2 glasses of wine daily or being obese. Estrogen-only HRT does not increase breast cancer risk and may actually decrease it slightly. The type of progestogen matters too — micronized progesterone appears to carry lower risk than synthetic progestins. This is a nuanced topic best discussed with your doctor using your personal risk profile.

What is the best age to start HRT? The safest and most beneficial window to start HRT is within 10 years of menopause onset or before age 60. This is called the “timing hypothesis” and is supported by multiple large studies. Starting within this window is associated with cardiovascular protection, better bone density outcomes, and a more favorable overall risk profile. Starting HRT after age 60 or more than 10 years past menopause carries higher cardiovascular risk and is generally not recommended for symptom relief alone.

Can I use supplements instead of HRT? Supplements can help with mild to moderate symptoms but are not equivalent to HRT in effectiveness. HRT reduces hot flashes by 75-90%, while the best-studied supplement (black cohosh) reduces them by 26-50%. For mild symptoms or women who cannot take HRT due to medical contraindications, supplements like black cohosh, magnesium, and evening primrose oil are reasonable options. For moderate to severe symptoms, HRT provides substantially more relief. Many women use both — supplements for additional support alongside HRT, or supplements as a bridge before deciding on HRT.

What are the side effects of HRT? Common side effects in the first few months include breast tenderness, bloating, headaches, and nausea — these usually resolve as your body adjusts. Irregular bleeding or spotting can occur in the first 3-6 months with combined HRT. Serious but rare risks include blood clots (primarily with oral estrogen — transdermal forms avoid this risk), stroke (mainly in women over 60), and a small increase in breast cancer with combined HRT after 5+ years. Most women tolerate HRT well, and side effects can often be managed by adjusting the dose or switching to a different formulation.

The Bottom Line

HRT is the most effective treatment for menopause symptoms, and the evidence supporting its safety for appropriately selected women is stronger than it has ever been. The 2002 WHI scare left a generation of women suffering needlessly — and while caution was understandable at the time, the science has moved forward substantially.

If your menopause symptoms are significantly affecting your quality of life — disrupted sleep, frequent hot flashes, mood changes that feel unmanageable, joint pain, vaginal dryness — HRT deserves a serious, informed conversation with your doctor. Not a fearful one driven by 20-year-old headlines, but a current one based on your individual risk profile and the updated evidence.

If your symptoms are mild, or if you have medical reasons not to take HRT, supplements and lifestyle changes remain valuable tools. Black cohosh, magnesium, and structured exercise won’t match HRT’s effectiveness, but they provide real, evidence-based relief for many women.

Whatever you choose, make it an informed choice. Fear shouldn’t drive the decision in either direction — neither the fear of hormones nor the fear of symptoms. You deserve accurate information, a doctor who takes your symptoms seriously, and the agency to decide what’s right for your body.

For related reading, see Perimenopause Symptoms and Supplements and Best Menopause Supplements.